摘要
风湿性关节炎(Rheumatoid Arthritis,RA)是一种常见的急性或慢性结缔组织炎症。临床常使用非甾体抗炎药、细胞毒素类免疫抑制剂或者糖皮质激素进行对症治疗。但至少有近5%的RA患者对常规治疗不敏感,惯称为难治愈性RA。已有研究表明,难治愈性RA与组织内P-糖蛋白过度表达有关。P-糖蛋白是由多重耐药基因-1编码的170kD跨膜转运蛋白。该蛋白功能是将药物小分子转运至细胞外,降低靶细胞内药物浓度。中医药治疗RA有着悠久的历史,文章以P-糖蛋白为靶点,对临床用于治疗RA常见中药进行整理。基于P-糖蛋白特殊的活性,对中药治疗RA的临床用药进行思考和展望。
Rheumatoid arthritis(RA)is a common acute or chronic connective tissue inflammation.Clinically,non-steroidal anti-inflammatory drugs,cytotoxic immunosuppressive agents or corticosteroids are used for symptomatic treatments in RA pa-tients.However,there are at least 5%of the RA patients who are not sensitive to conventional treatments.Previous studies have indicated that refractory RA is associated with the overexpression of P-glycoprotein in tissues.There is a long history for tradi-tional Chinese herb to cure RA.Based on P-glycoprotein,the common used anti-RA herbs in China are summarized.We also focused on rational use of traditional Chinese herb for treating RA in clinic———lessons learned from the target P-glycoprotein.
作者
肖锋
李路扬
王程
贺怡
许文成
XIAO Feng;LI Lu-yang;WANG Cheng;HE Yi;XU Wen-cheng(Hubei Provincial Hospital of Traditional Chinese Medicine,Wuhan Hubei 430064,China;Affiliated Hospital of Hubei University of Chinese Medicine,Wuhan Hubei 430064,China;Hubei Academy of Chinese Medicine,Wuhan Hubei 430064,China)
出处
《时珍国医国药》
CSCD
北大核心
2023年第10期2475-2478,共4页
Lishizhen Medicine and Materia Medica Research
基金
国家中医药管理局中药特色技术传承人才项目(国中医药办人教函[2018]204号)
湖北省武汉市中青年医学骨干人才培养工程(武卫通[2020]55号)
湖北省自然科学基金青年项目(2021CFB244)。
